Skip to main content

Table 3 The GRADE evidence quality for main outcome

From: The efficiency of risedronate in reducing bone resorption after total hip arthroplasty: a meta-analysis of randomized control trials at a minimum of 6 months’ follow-up

Quality assessment

No. of patients

Effect

Quality

Importance

No. of studies

Design

Limitations

Inconsistency

Indirectness

Imprecision

Other considerations

Risedronate groups

Control groups

Relative (95% CI)

Absolute

BMD in Gruen zone 1 at 6 months (follow-up 6 months; better indicated by lower values)

4

Randomized trials

No serious limitations

No serious inconsistency

No serious indirectness

No serious imprecision

None

97

101

SMD = 0.758, 95% CI 0.469 to 1.047

High

Critical

BMD in Gruen zone 2 at 6 months (follow-up 6 months; better indicated by lower values)

4

Randomized trials

No serious limitations

No serious inconsistency

No serious indirectness

No serious imprecision

None

97

101

SMD = 0.814, 95% CI 0.523 to 1.106

High

Critical

BMD in Gruen zone 3 at 6 months (follow-up 6 months; better indicated by lower values)

4

Randomized trials

No serious limitations

No serious inconsistency

No serious indirectness

No serious imprecision

None

97

101

SMD = 0.340, 95% CI 0.059 to 0.622

High

Critical

BMD in Gruen zone 4 at 6 months (follow-up 6 months; better indicated by lower values)

4

Randomized trials

No serious limitations

No serious inconsistency

No serious indirectness

No serious imprecision

None

97

101

SMD = 0.275, 95% CI − 0.007 to 0.556

High

Critical

BMD in Gruen zone 5 at 6 months (follow-up 6 months; better indicated by lower values)

4

Randomized trials

No serious limitations

Serious inconsistency

No serious indirectness

No serious imprecision

None

97

101

SMD = 0.204, 95% CI − 0.076 to 0.448

High

Critical

BMD in Gruen zone 6 at 6 months (follow-up 6 months; better indicated by lower values)

4

Randomized trials

No serious limitations

No serious inconsistency

No serious indirectness

No serious imprecision

None

97

101

SMD = 0.503, 95% CI 0.218 to 0.788

High

Critical

BMD in Gruen zone 7 at 6 months (follow-up 6 months; better indicated by lower values)

4

Randomized trials

No serious limitations

No serious inconsistency

No serious indirectness

No serious imprecision

None

97

101

SMD = 2.400, 95% CI 2.029 to 2.771

High

Critical